Apligraf denied due to quantity / dose limits by Cigna?

Cigna's specific coverage criteria for apligraf are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why Cigna Limits the Quantity of Apligraf Applications

Apligraf is a living cellular product applied directly to a wound surface. Cigna, like most payers, applies quantity or frequency limits tied to the number of applications per wound per treatment course. These limits are based on the scope of the FDA-cleared labeling and Cigna's own medical policy. A quantity-limit denial means that the number of applications requested or billed exceeded what the policy allows without additional documentation of continued clinical necessity.

## Why This Is Appealable

Quantity limits are not absolute. Cigna's medical policy — and the FDA-cleared labeling — typically contemplate that additional applications may be appropriate when a wound has shown a partial but incomplete response. If the wound is progressing (reducing in size, improving in depth) but has not fully closed, that trajectory is precisely the clinical evidence needed to justify continuation beyond the standard limit. The appeal must document wound response and explain why additional treatment is medically necessary.

## Federal Appeal Framework

• Internal appeal: File within the deadline on the denial letter. Include updated wound measurements and photographs.
• ACA §2719 external review: Available after exhausting internal appeals. IRO reviewers evaluate whether the quantity limit was appropriately applied given the clinical facts. Window is approximately four months from final internal denial.
• Expedited review: If delay in additional applications would result in significant harm (risk of amputation, infection, hospitalization), request expedited external review.
• ERISA §503: Requires that Cigna disclose the specific clinical rationale and criteria used to impose the limit.

## What to Gather

• Serial wound measurements: Objective measurements (length, width, depth) at each prior application visit, showing the wound trajectory.
• Wound photographs: Dated photographs from each visit demonstrating response or persistent need.
• Clinical notes: Treating clinician's assessment at each visit — not just the measurement, but the clinical interpretation of wound-healing progress.
• Prescriber continuation letter: A letter from the treating physician or podiatrist explaining why the wound has not closed, what progress has been made, and why additional applications are medically necessary rather than alternative interventions.
• FDA labeling reference: Confirm that the total number of applications requested is consistent with or addressed in the current FDA-cleared labeling; if the policy limit is more restrictive than the label, note that discrepancy.

## Criteria-Mapping Structure

In the appeal letter, document each prior application with its date, wound measurements before and after, and the clinical rationale for continuation. Map this directly to the language in Cigna's quantity-limit policy and the FDA labeling to demonstrate that continued use is consistent with both.